Literature DB >> 30996002

TNF and IL-1 Play Essential but Temporally Distinct Roles in Driving Cardiac Inflammation in a Murine Model of Kawasaki Disease.

Angus T Stock1, Hamdi A Jama2, Jacinta A Hansen3, Ian P Wicks1,4,5.   

Abstract

Kawasaki disease (KD) is a leading cause of pediatric heart disease, characterized by the emergence of life-threatening coronary vasculitis. Identifying which cytokines drive KD has been a major research goal, and both TNF and IL-1 have been identified as potential candidates. Using a murine model of KD induced by the injection of the water-soluble component of Candida albicans, we therefore undertook a mechanistic study to determine how and when these two cytokines mediate cardiac inflammation. In this study, we show that TNF signaling is active in the acute phase of cardiac inflammation, which is characterized by a diffuse myocarditis that precedes the development of coronary vasculitis. Mechanistically, TNF is produced by the myeloid cells and triggers acute cardiac inflammation by stimulating both stromal and immune compartments of the heart. In contrast to this early involvement for TNF, IL-1 signaling is dispensable for the development of acute myocarditis. Critically, although mice deficient in IL-1 signaling have extensive acute inflammation following C. albicans water-soluble complex challenge, they do not develop coronary vasculitis. Thus, TNF and IL-1 appear to play temporally distinct roles in KD, with TNF being active in acute cardiac inflammation and IL-1 in the subsequent development of coronary vasculitis. These observations have important implications for understanding the progression of cardiac pathology in KD and the relative therapeutic use of targeting these cytokines.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30996002     DOI: 10.4049/jimmunol.1801593

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Interleukin-1 Beta-Mediated Sex Differences in Kawasaki Disease Vasculitis Development and Response to Treatment.

Authors:  Rebecca A Porritt; Janet L Markman; Daisuke Maruyama; Begum Kocaturk; Shuang Chen; Thomas J A Lehman; Youngho Lee; Michael C Fishbein; Magali Noval Rivas; Moshe Arditi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-01-30       Impact factor: 8.311

2.  Melatonin alleviates vascular endothelial cell damage by regulating an autophagy-apoptosis axis in Kawasaki disease.

Authors:  Yuanzheng Zheng; Saihua Huang; Jialing Zhang; Jia Hou; Fang Wu; Wenji Wang; Xiao Han; Yonghao Gui
Journal:  Cell Prolif       Date:  2022-05-17       Impact factor: 8.755

Review 3.  Kawasaki disease: pathophysiology and insights from mouse models.

Authors:  Magali Noval Rivas; Moshe Arditi
Journal:  Nat Rev Rheumatol       Date:  2020-05-26       Impact factor: 20.543

Review 4.  Kawasaki Disease and Multisystem Inflammatory Syndrome in Children with COVID-19.

Authors:  Mojdeh Sarzaeim; Nima Rezaei
Journal:  SN Compr Clin Med       Date:  2020-10-06

5.  Inhibition of IL-6 in the LCWE Mouse Model of Kawasaki Disease Inhibits Acute Phase Reactant Serum Amyloid A but Fails to Attenuate Vasculitis.

Authors:  Rebecca A Porritt; Carol Chase Huizar; Edward J Dick; Shyamesh Kumar; Renee Escalona; Angela C Gomez; Stefani Marek-Iannucci; Magali Noval Rivas; Jean Patterson; Thomas G Forsthuber; Moshe Arditi; Mark Gorelik
Journal:  Front Immunol       Date:  2021-04-09       Impact factor: 7.561

6.  Neutropenia Is Not Associated With the Outcomes in Patients With Kawasaki Disease.

Authors:  Yunjia Tang; Miao Gang; Weiguo Qian; Jin Ma; Qiuqin Xu; Haitao Lv
Journal:  Front Pediatr       Date:  2021-06-04       Impact factor: 3.418

7.  CDCP1 on Dendritic Cells Contributes to the Development of a Model of Kawasaki Disease.

Authors:  Yu Lun; Nozha Borjini; Noriko N Miura; Naohito Ohno; Nora G Singer; Feng Lin
Journal:  J Immunol       Date:  2021-06-07       Impact factor: 5.426

Review 8.  Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease.

Authors:  Bin Tang; Hang Hong Lo; Cheng Lei; Ka In U; Wen-Luan Wendy Hsiao; Xiaoling Guo; Jun Bai; Vincent Kam-Wai Wong; Betty Yuen-Kwan Law
Journal:  Phytomedicine       Date:  2020-03-18       Impact factor: 5.340

9.  Complete Regression of Giant Aneurysms in an Infant with Delayed Diagnosis and Refractory Kawasaki Disease via Combination Anticytokine Therapy: Case Report and Review of Similar Cases.

Authors:  Maegan Williams; Lakshmi Nagaraju; Mark Gorelik
Journal:  Case Rep Rheumatol       Date:  2020-03-28

10.  Functional benefits of corticosteroid and IVIG combination therapy in a coronary artery endothelial cell model of Kawasaki disease.

Authors:  Takashi Inoue; Shokei Murakami; Kenji Matsumoto; Akio Matsuda
Journal:  Pediatr Rheumatol Online J       Date:  2020-10-06       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.